



23ANDME FACT SHEET	
Mission and Vision	23andMe is a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome.
The 23andMe Genetic Discovery Platform	<p>23andMe has built the most comprehensive and diverse genetic research platform, powering new insights for customers, and the ability to more efficiently identify novel therapeutic targets.</p> <ul style="list-style-type: none"> ● 23andMe pioneered a revolutionary approach to research, putting people at the center of the experience. We make it simple and empowering for customers to participate in studies through our online platform. ● This crowdsourced approach, coupled with the ability to recontact participants, allows 23andMe research to operate on an unparalleled scale. ● 23andMe research facts: <ul style="list-style-type: none"> ○ 13+ million genotyped customers, more than 80% of whom consent to participate in research ○ 4+ billion phenotypic data points (survey answers) collected to date ○ ~30K surveys completed per day by consented customers ○ 200+ peer reviewed publications, 10,000 + citations
23andMe Services	<p>Vision for Personalized Health Services Through Genetics</p> <ul style="list-style-type: none"> ● We hope to empower people through access and understanding of their genetic data. We believe learning about your genetic health information can help you make better decisions. ● 23andMe is the only direct-to-consumer company with multiple FDA authorizations for genetic health reports. ● Genetics is a necessary component to better understanding your health - it provides a more complete picture, and should be a core part of primary care along with family health history. <ul style="list-style-type: none"> ○ With 23andMe services, customers can learn valuable information about their own health and genetic predispositions to certain cancers and other diseases such as type 2 diabetes, heart disease, certain conditions that impact fertility, and how your genetics may impact how you process certain medications, in order to make lifestyle changes or take preventative action with a healthcare provider. ● We are in the process of integrating genetic health information into primary care through services provided by 23andMe and Lemonaid Health, an on-demand platform for accessing medical care and pharmacy services online, acquired by 23andMe in November 2021. <ul style="list-style-type: none"> ○ Lemonaid Health has a telemedicine and digital pharmacy platform that allows patients to get care and treatment for certain conditions easily from the comfort of their home. ○ As of May 2022, 23andMe customers can now schedule consultations with Lemonaid Health health care providers on select 23andMe health reports. ○ Personalized health care consults will provide health recommendations to customers and help them understand how their genetic risk factors can play a role in their personal and family health history. <p>What Services Does 23andMe Offer?</p> <ul style="list-style-type: none"> ● The Health + Ancestry Service offers 150+ personalized genetic reports. <ul style="list-style-type: none"> ○ Health Predispositions (includes both reports that meet FDA requirements for Genetic Health Risks and reports powered by 23andMe research)*, including 10+ reports, such as

	<p>BRCA1/BRCA2 (Selected Variants), Parkinson’s Disease and Type 2 Diabetes (Powered by 23andMe Research)</p> <ul style="list-style-type: none"> ○ Carrier Status,* featuring 40+ reports, including Cystic Fibrosis, Sickle Cell Anemia and Tay-Sachs Disease ○ Wellness, including 5+ reports including Deep Sleep, Lactose Intolerance, Genetic Weight and Caffeine Consumption ○ Traits, featuring 30+ reports including information, such as early hair loss, sweet vs. salty, and unibrow. <ul style="list-style-type: none"> ● The Ancestry Service provides a breakdown of global ancestry composition by percentages, with 35+ reports that provide information about ancestry composition, haplogroups and Neanderthal ancestry, as well as inheritance tracing and the option to connect with DNA Relatives. <ul style="list-style-type: none"> ○ 23andMe can evaluate a customer’s ancestry based on 2,000+ specific regions and the Service now includes an automatic, DNA-based family tree builder. ○ Customers can also access 30+ Traits reports at no additional cost (see Trait reports above). ● 23andMe + Membership is an annual membership with access to more than 30 exclusive reports with new premium reports and features delivered to you throughout the year to keep fueling your health journey. <ul style="list-style-type: none"> ○ Includes everything from 23andMe’s Health + Ancestry Service - all 150+ personalized genetic reports - plus ongoing genetic insights that help you learn about your heart health, how genetics may impact how you process certain medications**, migraines, and more. <p>Lemonaid Health</p> <ul style="list-style-type: none"> ● Lemonaid Health provides an on-demand platform for accessing affordable medical care and pharmacy services online, from consultation through treatment, for a number of common conditions. ● 23andMe acquired Lemonaid Health, Inc., in November of 2021, adding Lemonaid’s innovative telemedicine and prescription drug delivery services to 23andMe’s consumer services. ● Lemonaid Health uses evidence-based guidelines and up-to-date clinical protocols to provide affordable quality care. ● Patients can be prescribed medications through the platform, with fast and free delivery, increasing the speed, accessibility, and efficiency of treatment.*** ● Combining Lemonaid Health’s telemedicine platform, including its online team of licensed medical professionals, lab services and its pharmacy services, with 23andMe genetic insights marks an important step in transforming the traditional primary care experience and making personalized healthcare a reality.
<p>23andMe Therapeutics</p>	<ul style="list-style-type: none"> ● 23andMe Therapeutics is conducting drug discovery and development from target identification through clinical stages, using genetic insights from 23andMe’s proprietary database as a foundation; we believe this approach - starting with human genetic evidence - is a far more efficient way to develop novel therapeutics. ● The Therapeutics group is helmed by an accomplished leadership team with a wealth of experience in target discovery, data analytics, biostatistics, biology, and clinical development. ● By studying genetics data at scale, we can derive new insights into human biology, including how our genetics impact disease. Our scientists study the aggregate, de-identified genetics of consented research participants, alongside more than 4 billion health survey answers from consented research participants.

- Analyzing both genetic data and health survey responses, 23andMe identifies unique, disease-specific genetic “signatures” and pinpoint areas of the genome that may be promising for therapeutic intervention.
- These signatures are more likely to be recognized by 23andMe due to the enormous size of the company’s genomic and health survey databases.
- Studies have shown that therapeutic programs with a human genetic foundation are more than twice as likely to succeed³.
- Currently, there are 2 clinical trials with 23andMe-validated targets underway, including the company’s first wholly-owned immuno-oncology program (more below).
- 23andMe also has more than 50² earlier stage drug development programs underway.

Two clinical trials underway

- For each of the targets in these trials, 23andMe analyzed its proprietary genetic and health survey database to identify an immuno-oncology genetic signature, which defines areas of the genome that have opposing associations with cancer and autoimmune disease. This indicates the target may be promising as an immuno-therapy candidate.
- **23ME-00610 - an Investigational Antibody Targeting CD200R1**
 - The Phase 2a portion of 23andMe’s Phase 1/2a study of 23ME-00610, an investigational antibody targeting CD200R1 in patients with advanced solid malignancies, is currently underway. 23andMe [announced](#) the first patient dosed in the Phase 2a portion of the study in February 2023.
 - The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610.
 - Many cancers are able to escape the immune system, allowing them to grow in the body unchecked. Therefore, drugs that enhance immune-cell activity, or the ability of immune cells to recognize cancer cells, have the potential to be powerful anti-cancer therapies.
 - CD200R1 is a cell surface receptor protein that is mostly expressed on human immune cells, specifically cancer-fighting T cells and myeloid cells. Tumor cells can express CD200, the only known binding partner for CD200R1, and use this regulatory protein to turn off the activity of T cells.
 - A drug that blocks the ability of CD200 to bind to CD200R1 may activate T cells and enhance their ability to kill cancer cells.
 - 23andMe analyzed its proprietary genetic and health survey database to identify an immuno-oncology genetic signature, which defines areas of the genome that have opposing associations with cancer and autoimmune diseases.
 - Using this approach, 23andMe scientists discovered that three components of the CD200R1 pathway exhibit an immuno-oncology genetic signature, including the CD200R1 receptor, the CD200 ligand, and DOK2, a mediator of downstream signaling from CD200R1.
 - Following this genetic insight, 23andMe subsequently generated data consistent with CD200R1’s role in inhibiting anti-cancer responses in immune cells.
 - Clinical data from the Phase 1 portion of this program is anticipated to be presented at a scientific conference in CY2023.
- **GSK6097608 - an immuno-oncology therapeutic mAb targeting CD96¹**
 - *(Note: 23andMe announced it is taking the royalty option for this program, whereby the company receives royalties on future sales, and is no longer involved in the therapeutic development of this program)*

	<ul style="list-style-type: none"> ○ The program is an immuno-oncology therapeutic mAb targeting CD96 called GSK6097608. CD96 sequesters a shared ligand (CD155) away from the costimulatory receptor (CD226), effectively attenuating T and NK cell anti-tumor immune responses. ○ By blocking CD96, GSK6097608 may allow activation of CD226 and enhance anti-tumor immunity through T and NK cells. ○ CD226 was validated using our proprietary immuno-oncology genetic signature (see above).
References and Disclaimers	<p>¹ GSK is solely responsible for the development of GSK6097608 (GSK'608) in later-stage clinical trials. Subject to its successful commercialization, 23andMe is eligible to earn tiered worldwide royalties up to the low double digits.</p> <p>² The 50+ programs in the combined therapeutic areas include 100% owned and royalty interest targets as well as those in collaborations. The majority of the programs are in collaboration with GSK. Note: As of March 31, 2022</p> <p>³ Nelson et al., 2015 (Nature Genetics), King et al., 2019 (PLOS Genetics)</p> <p>**The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person's overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk.</p> <p>Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/.</p> <p>**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not</p>

describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. **Warning:** Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit www.23andme.com/test-info.

*** Medication only available if prescribed. FDA-approved. Individual results vary. Prescription requires online consultation with licensed healthcare provider through the Lemonaid online platform. See www.lemonaidhealth.com to learn more. U.S. only.